World Cardiac Biomarkers Market

World Cardiac Biomarkers Market

This report analyzes the worldwide markets for Cardiac Biomarkers in Millions of US$. The market is analyzed by Location-wise (Clinical Laboratory Testing, and Point-of-Care Testing) and by Assay type-wise (Acute Myocardial Infarction (AMI) Tests (Creatine Kinase-MB (CK-MB), Cardiac Troponin, & Myoglobin), and Congestive Heart Failure (CHF) Tests (BNP &NT-proBNP)). The report provides separate omprehensive analytics for the US, Europe, and Rest of the World. Annual forecasts are provided for each region for the period of 2006 through 2015. A five-year historic analysis is also provided for these markets. The report profiles 78 companies including many key and niche players worldwide such as Abbott Diagnostics, Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., biomérieux, Inverness Medical Innovations, Inc., LifeSign LLC, Nanogen Inc., Ortho-Clinical Diagnostics, Inc., Oxis International, Inc., Prognostix, Inc., Response Biomedical Corp., Roche Diagnostics Corp., and Siemens Healthcare Diagnostics, Inc..Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CARDIAC BIOMARKERS
A GLOBAL STRATEGIC BUSINESS REPORT MCP-1632


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3


II. EXECUTIVE SUMMARY

1. Industry Review II-1
Cardiovascular Diseases: Leading cause of Mortality Worldwide II-1
Table 1: Region-wise Incidence & Prevalence of Cardiovascular
Diseases in 2006 II-1
Basic Topologies of Cardiovascular Diseases II-1
Fast and Accurate Diagnosis - Reduce Unnecessary Healthcare Costs II-2
Cardiac Biomarkers - Making Diagnosis Easier and Quicker II-2
What is a Cardiac Marker: II-3
Necessity of a Cardiac Marker Assay Test II-3
How it works? II-3
Major Cardiac Markers and their Properties II-4
Market Analysis II-4
Market Trends II-5
Strong Demand for Risk Assessment Markers II-5
Intense Competition among Players in the Cardiac Diagnostics
Market II-5
The Future of Cardiac Marker POCT Segment II-5
Need for Early Detection Markers II-6
Rapid Turnaround time: A Crucial Parameter for POC Testing Kits II-6

2. Competitive Analysis II-7
Siemens Healthcare becomes the leader, after a series of
Acquisitions II-7
Product Portfolio of Bayer and Dade Behring II-7

3. Cardiac Markers and Myocardial Infarction II-9
Chain Reaction After an Event of MI II-9
Action Plan after an Event of MI II-9
Protocol for Conducting AMI Markers Tests II-10
Myocardial Infarction Cardiac Biomarkers - Benefits and
Limitations II-10
Creatine Kinase - The Traditional Gold Standard, Loosing Sheen II-10
Market and Forecasts: II-11
Isomers II-11
Kinetics II-11
Purpose of Test and When to Order II-11
Evaluation II-11
Points to remember II-11
Cardiac Troponin - Taking Over from CK-MB II-12
Market and Forecast II-12
Overview II-12
Troponin Tissue-Specific Subtypes II-12
Other Diseases II-13
Uses of Troponin Tests II-13
New Advanced High-sensitivity (Hs) Cardiac Troponin Tests II-13
Myoglobin II-13
Purpose of Test and When to Order II-14
Testing and Evaluation II-14
Points to Remember II-14
Market and Forecast II-14

4. Cardiac Markers and Congestive Heart Failure (CHF) II-15
Key Facts II-15
BNP (B-type Natriuretic Peptide) II-15
NT-proBNP (N-terminal proBNP) II-16
Purpose of Tests and When to Order II-16
Testing and Evaluation II-16
Points to Remember II-16
Market and Forecast II-17
Market Characteristics II-17
Choosing the Right BNP and NT proBNP Assay Kit in the Market II-18
Evolution of BNP and NT proBNP Market II-18
NT-proBNP is superior to BNP in Predicting Mortality in Heart
Failure Patients, with Reduced Kidney Function II-19

5. Stroke Biomarkers - A Review II-20
Player Initiatives II-20
Other Important Cardiac Biomarkers II-21
Homocysteine II-21
C-Reactive Protein II-21
Plasminogen Activator Inhibitor-1 II-22
D-Dimer II-22
Thrombus Precursor Protein II-22
Potential Future Cardiac Biomarkers II-22

6. Cardiac Biomarker Testing in Clinical Laboratories II-25
Market and Forecast II-25
Leading Players in Laboratory Cardiac Markers II-25

7. Cardiac Biomarkers at Point-of-Care Testing II-26
Market and Forecast II-26
Major Players Operating in the Cardiac Markers POCT Segment II-27
Cardiac Markers Point-of-Care testing (POCT) Segment: Major
Players & Their Operating Brands. II-27

8. Strategic Corporate Developments II-28
Response Biomedical Signs Partnership Agreement with Roche II-28
Nanogen and Elitech Plans to Merge II-28
Compugen Announces Discovery of Troponin I Biomarker Variant,
Inks Agreement with Biosite II-28
Inverness Acquires Biosite II-29
Siemens Acquires Diagnostic Division of Bayer Healthcare II-29
Siemens Announces Acquisition of Dade Behring II-29
Beckman Collaborates in CVD Related Research Projects II-29
Dade Behring Receives Sublicense to New Cardiac Marker II-30
Inverness Acquires Cholestech II-30
Response Biomedical Secures Clearance to Market RAMP® NT-
proBNP Test II-30
Acrongenomics Collaborates with Molecular Vision and Pearson
Matthews II-30
BG Medicine Obtains Rights to Develop Tests for Congestive
Heart Failure II-31
Nanogen Gains US Reissue Patent for Combined Use of Biomarkers
for CHF Diagnosis II-31
Nanogen Secures FDA Approval for CHF NT-proBNP EDTA Plasma Test II-31
Roche Diagnostics Secures FDA Approval for Roche Elecsys®
proBNP Test II-31
Nanogen Acquires Rapid Cardiac Immunoassay Test Businesses of SDI II-32
Response Biomedical Starts Clinical Trials of the RAMP NT-
proBNP Test II-32
Procter and Gamble, Inverness to Form JV for Consumer Diagnostics II-32
Roche Diagnostics Grants Rights for NT- proBNP to Mitsubishi
Kagaku Latron II-33
Bayer Healthcare Receives FDA Approval for Troponin-I-Test
Tnl-Ultra II-33
MKI Obtains EU Approval and CE Mark for Four Cardiac Markers II-33
Dade Behring Grants PIGF Rights to Abbott II-33
OXIS International Acquires Biocheck II-33
Wampole, Roche collaborate on Ischemia Modified Albumin Test II-34
Nanogen Extends Point-of-Care Diagnostic Tests Distribution in
Europe II-34
Abbott, Cleveland Clinic Agrees to Develop MPO Cardiac Test II-34
Response Biomedical Receives Non-exclusive Rights to Roche’s
Cardiac Markers II-34
Roche Diagnostics Grants Rights to Response Biomedical for
Troponin T and NT- proBNP II-35
Inverness to Acquire Ischemia Technologies II-35
Roche Diagnostics Grants Rights for NT- proBNP to bioMerieux II-36
Roche Confers Rights of NT-proBNP to Ortho-Clinical Diagnostics II-36
Dade Behring Grants CRP Sublicense to Roche Diagnostics II-36
Roche Awards Non Exclusive Rights of NT-proBNP marker to DPC II-36
Abbott Gains Approval for CK-MB Test in the US II-37
i-STAT Gains Approval for Troponin I Test from US FDA II-37

9. Product Launches/Developments/Approvals II-38
Response Bags FDA Clearance for RAMP® NT-proBNP Test II-38
bioMérieux Rolls out VIDAS® NT-proBNP II-38
Roche Diagnostics Introduces Cobas-H-232 Handheld Cardiac
Marker System II-38
OXIS Discovers a Unique Diagnostic Biomarker for
Cardiovascular Disease II-38
Ortho-Clinical Presents Sensitivity Troponin I Test, VITROS
Troponin I ES II-39
bioMerieux Unveils ‘VIDAS® Troponin I Ultra’ II-39
Roche Elecsys proBNP Assay Secures FDA Clearance II-39
Bayer Launches New Tnl-Ultra™ Troponin Assay on ADVIA Centaur®
CP Immunoassay system II-40
Ortho-Clinical Diagnostics Receives FDA Clearance for VITROS
NT-proBNP Assay II-40
Dade Behring Launches CardioPhase® hsCRP Test II-40
Diagnostic Products Corporation to Market NT-proBNP Outside US II-41
Dade Behring Introduces Homocysteine Assay for BN™ System II-41
Biosite Develops Triage® Cardio ProfilER™ Panel II-41
A Breakthrough Biochip Array System for MI II-41
FDA Approves Emergency Department Diagnostic Test from Biosite II-42
Response Biomedical Obtains Regulatory Clearance for RAMP® II-42
Response Biomedical Gains US FDA Approval for 3rd RAMP® Test II-42
CLINIQA Rolls Out Liquid Stable Cardiac Marker Controls II-42
Abbott Releases AxSYM® Troponin-I ADV Assay in World Markets II-43

10. Focus on Select Global Players II-44
Abbott Diagnostics (USA) II-44
Ani Biotech Oy (Finland) II-44
Axis-Shield PoC (UK) II-44
Beckman Coulter, Inc. (USA) II-45
biomérieux (France) II-45
Inverness Medical Innovations, Inc. (USA) II-45
LifeSign LLC (USA) II-46
Nanogen Inc. (USA) II-46
Ortho-Clinical Diagnostics, Inc. (USA) II-46
Oxis International, Inc. (USA) II-47
Prognostix, Inc. (USA) II-47
Response Biomedical Corp. (Canada) II-47
Roche Diagnostics Corp. (USA) II-47
Siemens Healthcare Diagnostics, Inc. (USA) II-48

11. Global Market Perspective II-49
Table 2: World Recent Past, Current and Future Analysis for
Cardiac Biomarkers by Geographic Region - US, Europe, and Rest
of the World Markets Independently Analyzed with Annual Sales
Figures in US$ million for Years 2006 through 2015 (includes
corresponding Graph/Chart) II-49

Table 3: World Historic Review Analysis for Cardiac Biomarkers
by Geographic Region - US, Europe, and Rest of the World
Markets Independently Analyzed with Annual Sales Figures in
US$ million for Years 2001 through 2005 (includes
corresponding Graph/Chart) II-50

Table 4: World 10-Year Perspective for Cardiac Biomarkers by
Geographic Region - US, Europe, and Rest of the World Markets
Independently Analyzed with Annual Sales Figures in US$
million for Years 2006, 2009, and 2015 (includes corresponding
Graph/Chart) II-50

Table 5: World Recent Past, Current and Future Analysis for
Cardiac Biomarkers in Laboratory Testing Sector by Geographic
Region - US, Europe, and Rest of the World Markets
Independently Analyzed with Annual Sales Figures in US$
million for Years 2006 through 2015 (includes corresponding
Graph/Chart) II-51

Table 6: World Historic Review Analysis for Cardiac Biomarkers
in Laboratory Testing Sector by Geographic Region - US,
Europe, and Rest of the World Markets Independently Analyzed
with Annual Sales Figures in US$ million for Years 2001
through 2005 (includes corresponding Graph/Chart) II-52

Table 7: World 10-Year Perspective for Cardiac Biomarkers in
Laboratory Testing Sector by Geographic Region - US, Europe,
and Rest of the World Markets Independently Analyzed with
Annual Sales Figures in US$ million for Years 2006, 2009, and
2015 (includes corresponding Graph/Chart) II-52

Table 8: World Recent Past, Current and Future Analysis for
Cardiac Biomarkers in Point-of-Care Testing Sector by
Geographic Region - US, Europe, and Rest of the World Markets
Independently Analyzed with Annual Sales Figures in US$
million for Years 2006 through 2015 (includes corresponding
Graph/Chart) II-53

Table 9: World Historic Review Analysis for Cardiac Biomarkers
in Point-of-Care Testing Sector by Geographic Region - US,
Europe, and Rest of the World Markets Independently Analyzed
with Annual Sales Figures in US$ million for Years 2001
through 2005 (includes corresponding Graph/Chart) II-54

Table 10: World 10-Year Perspective for Cardiac Biomarkers in
Point-of-Care Testing Sector by Geographic Region - US,
Europe, and Rest of the World Markets Independently Analyzed
with Annual Sales Figures in US$ million for Years 2006, 2009,
and 2015 (includes corresponding Graph/Chart) II-54

Table 11: World Recent Past, Current & Future Analysis for
CK-MB Assay Test by Geographic Region- US, Europe and Rest of
the World Markets. Independently Analyzed with Annual Sales
Figures in US$ million for Years 2006 through 2015 (includes
corresponding Graph/Chart) II-55

Table 12: World Historic Review Analysis for CK-MB Assay Test
by Geographic Region- US, Europe and Rest of the World
Markets. Independently Analyzed with Annual Sales Figures in
US$ million for Years 2001 through 2005 (includes
corresponding Graph/Chart) II-56

Table 13: World 10-Year Perspective for CK-MB Assay Test by
Geographic Region- US, Europe and Rest of the World Markets.
Independently Analyzed with Annual Sales Figures in US$
million for Years 2006, 2009, and 2015 (includes corresponding
Graph/Chart) II-56

Table 14: World Recent Past, Current & Future Analysis for
Cardiac Troponin Assay Test by Geographic Region- US, Europe
and Rest of the World Markets. Independently Analyzed with
Annual Sales Figures in US$ million for Years 2006 through
2015 (includes corresponding Graph/Chart) II-57

Table 15: World Historic Review Analysis for Cardiac Troponin
Assay Test by Geographic Region- US, Europe and Rest of the
World Markets. Independently Analyzed with Annual Sales
Figures in US$ million for Years 2001 through 2005 (includes
corresponding Graph/Chart) II-58

Table 16: World 10-Year Perspective for Cardiac Troponin Assay
Test by Geographic Region- USA, Europe and Rest of the World
Markets. Independently Analyzed with Annual Sales Figures in
US$ million for Years 2006, 2009, and 2015 (includes
corresponding Graph/Chart) II-58

Table 17: World Recent Past, Current & Future Analysis for
Myoglobin Assay Test by Geographic Region- US, Europe and Rest
of the World Markets. Independently Analyzed with Annual Sales
Figures in US$ million for Years 2006 through 2015 (includes
corresponding Graph/Chart) II-59

Table 18: World Historic Review Analysis for Myoglobin Assay
Test by Geographic Region- US, Europe and Rest of the World
Markets. Independently Analyzed with Annual Sales Figures in
US$ million for Years 2001 through 2005 (includes
corresponding Graph/Chart) II-60

Table 19: World 10-Year Perspective for Myoglobin Assay Test
by Geographic Region- US, Europe and Rest of the World
Markets. Independently Analyzed with Annual Sales Figures in
US$ million for Years 2006, 2009, and 2015 (includes
corresponding Graph/Chart) II-60

Table 20: World Recent Past, Current & Future Analysis for BNP
& NT-proBNP Assay Test by Geographic Region- US, Europe and
Rest of the World Markets. Independently Analyzed with Annual
Sales Figures in US$ million for Years 2006 through 2015
(includes corresponding Graph/Chart) II-61

Table 21: World Historic Review Analysis for BNP & NT-proBNP
Assay Test by Geographic Region- US, Europe and Rest of the
World Markets. Independently Analyzed with Annual Sales
Figures in US$ million for Years 2001 through 2005 (includes
corresponding Graph/Chart) II-62

Table 22: World 10-Year Perspective for BNP & NT-proBNP Assay
Test by Geographic Region- US, Europe and Rest of the World
Markets. Independently Analyzed with Annual Sales Figures in
US$ million for Years 2006, 2009, and 2015 (includes
corresponding Graph/Chart) II-62


III. MARKET

1. The United States III-1
A.Market Analysis III-1
Cardiovascular Diseases in US: A Review III-1
Table 23: The US Disease Statistics for Coronary Heart
Disease (CHD) & Myocardial Infarction (MI) III-1
Table 24: The US Prevalence of Coronary Heart Disease (CHD)
as a Percentage of Total Population by Age-group & Sex, in
2005 - 06. (includes corresponding Graph/Chart) III-2

Table 25: The US Annual Number of New & Recurrent Adults
diagnosed with Heart Attack by Age & Sex in the Recent Past
(includes corresponding Graph/Chart) III-2

Table 26: The US Disease Statistics for Heart Failure III-2

Table 27: The Annual Number of Americans Diagnosed with
Heart Failure as 'per 1000 persons' by Age & Sex, in the
Recent Past (includes corresponding Graph/Chart) III-3
30% Fall in Number of Deaths due to Heart Diseases & Strokes
Over Last Decade III-3
Senior Citizens at High Risk for Heart Failure III-3
CHF Biomarkers to Spearhead the US market III-4
US Cardiac Markers POCT Segment III-4
Table 28: US AMI (Acute Myocardial Infarction) Diagnostics
Market: Market Share by Revenue held by Major Players (Dade
Behring, Beckman Coulter, Bayer Diagnostics, and Others) in
2006 (includes corresponding Graph/Chart) III-5

Table 29: US CHF (Congestive Heart Failure) Diagnostics
Market: Market Share by Revenue held by Major Players (Dade
Behring, Beckman Coulter, Bayer Diagnostics, and Others) in
2006 (includes corresponding Graph/Chart) III-5

Table 30: US Laboratory Testing Segment: Market Share by
Revenue held by Major Players (Abbott, Dade Behring, Bayer,
Beckman Coulter, Roche, Ortho-clinical, and Others) in 2001
(includes corresponding Graph/Chart) III-5
Product Launches/Approvals/Developments III-6
Strategic Corporate Developments III-10
Key Players III-17
Abbott Diagnostics III-17
Beckman Coulter, Inc. III-17
diaDexus, Inc. III-18
Inverness Medical Innovations, Inc. III-18
LifeSign LLC III-18
Nanogen Inc. III-18
Ortho-Clinical Diagnostics, Inc. III-19
Oxis International, Inc. III-19
Prognostix, Inc. III-19
Roche Diagnostics Corp. III-20
Siemens Healthcare Diagnostics, Inc. III-20
B.Market Analytics III-21
Table 31: US Recent Past, Current and Future Analysis for
Cardiac Markers by Segment - Clinical Laboratory testing and
Point-of-Care Testing (POCT) Markets: Independently Analyzed
with Annual Sales in US$ million for Years 2006 through 2015
(includes corresponding Graph/Chart) III-21

Table 32: US Historic Review Analysis for Cardiac Markers by
Segment - Clinical Laboratory testing and Point-of-Care
Testing (POCT) Markets: Independently Analyzed with Annual
Sales in US$ million for Years 2001 through 2005 (includes
corresponding Graph/Chart) III-21

Table 33: US 10-Year Perspective for Cardiac Markers by
Segment - Clinical Laboratory testing and Point-of- Care
Testing (POCT) Markets: Independently Analyzed with Annual
Sales in US$ million for 2006, 2009 and 2015 III-22

Table 34: US Recent Past, Current and Future Analysis for
Cardiac Markers by Test Type - AMI (CK-MB, Cardiac Troponin
and Myoglobin), and CHF (BNP and NT proBNP) Markets:
Independently Analyzed with Annual Sales in US$ million for
Years 2006 through 2015 (includes corresponding Graph/Chart) III-23

Table 35: US Historic Review Analysis for Cardiac Markers by
Test Type - AMI (CK-MB, Cardiac Troponin and Myoglobin), and
CHF (BNP and NT proBNP) Markets: Independently Analyzed with
Annual Sales in US$ million for Years 2001 through 2005
(includes corresponding Graph/Chart) III-24

Table 36: US 10-Year Perspective for Cardiac Markers by Test
Type - AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF
(BNP and NT proBNP) Markets: Independently Analyzed with
Annual Sales in US$ million for 2006, 2009 and 2015
(includes corresponding Graph/Chart) III-25

2. Europe III-26
A.Market Analysis III-26
European Cardiovascular Diseases Fact Sheet III-26
Evolution of the European Cardiac Risk Markers Market III-26
Cardiac Markers in Primary Care Sector III-27
Product Launches/Approvals/Developments III-27
Strategic Corporate Developments III-28
B.Market Analytics III-29
Table 37: European Recent Past, Current and Future Analysis
for Cardiac Markers by Region - France, Germany, Italy, UK,
and ‘Rest of Europe’ Markets: Independently Analyzed with
Annual Sales in US$ million for Years 2006 through 2015
(includes corresponding Graph/Chart) III-29

Table 38: European Historic Review Analysis for Cardiac
Markers by Region - France, Germany, Italy, UK, and ‘Rest of
Europe’ Markets: Independently Analyzed with Annual Sales in
US$ million for Years 2001 through 2005 (includes
corresponding Graph/Chart) III-30

Table 39: European 10-Year Perspective for Cardiac Markers
by Region - France, Germany, Italy, UK, and ‘Rest of Europe’
Markets: Independently Analyzed with Annual Sales in US$
million for 2006, 2009 and 2015 (includes corresponding
Graph/Chart) III-31

Table 40: European Recent Past, Current and Future Analysis
for Cardiac Markers by Segment - Clinical Laboratory testing
and Point-of-Care Testing (POCT) Markets: Independently
Analyzed with Annual Sales in US$ million for Years 2006
through 2015 (includes corresponding Graph/Chart) III-32

Table 41: European Historic Review Analysis for Cardiac
Markers by Segment - Clinical Laboratory testing and
Point-of-Care Testing (POCT) Markets: Independently Analyzed
with Annual Sales in US$ million for Years 2001 through 2005
(includes corresponding Graph/Chart) III-32

Table 42: European 10-Year Perspective for Cardiac Markers
by Segment - Clinical Laboratory testing and Point-of-Care
Testing (POCT) Markets: Independently Analyzed with Annual
Sales in US$ million for 2006, 2009 and 2015 III-33

Table 43: European Recent Past, Current and Future Analysis
for Cardiac Markers by Assay Test Type - AMI (CK-MB, Cardiac
Troponin and Myoglobin), and CHF (BNP and NT proBNP)
Markets: Independently Analyzed with Annual Sales in US$
million for Years 2006 through 2015 (includes corresponding
Graph/Chart) III-34

Table 44: European Historic Review Analysis for Cardiac
Markers by Assay Test Type - AMI (CK-MB, Cardiac Troponin
and Myoglobin), and CHF (BNP and NT proBNP) Markets:
Independently Analyzed with Annual Sales in US$ million for
Years 2001 through 2005 (includes corresponding Graph/Chart) III-35

Table 45: European 10-Year Perspective for Cardiac Markers
by Assay Test Type - AMI (CK-MB, Cardiac Troponin and
Myoglobin), and CHF (BNP and NT proBNP) Markets:
Independently Analyzed with Annual Sales in US$ million for
2006, 2009 and 2015 (includes corresponding Graph/Chart) III-36

2a. France III-37
A.Market Analysis III-37
Product Launches/Approvals/Developments III-37
Strategic Corporate Developments III-38
Key Players III-38
B.Market Analytics III-39
Table 46: French Recent Past, Current and Future Analysis
for Cardiac Markers by Segment - Clinical Laboratory testing
and Point-of-Care Testing (POCT) Markets: Independently
Analyzed with Annual Sales in US$ million for Years 2006
through 2015 (includes corresponding Graph/Chart) III-39

Table 47: French Historic Review Analysis for Cardiac
Markers by Segment - Clinical Laboratory testing and
Point-of-Care Testing (POCT) Markets: Independently Analyzed
with Annual Sales in US$ million for Years 2001 through 2005
(includes corresponding Graph/Chart) III-39

Table 48: French 10-Year Perspective for Cardiac Markers by
Segment - Clinical Laboratory testing and Point-of-Care
Testing (POCT) Markets: Independently Analyzed with Annual
Sales in US$ million for 2006, 2009 and 2015 III-40

2b. Germany III-41
A.Market Analysis III-41
Rennesens GmbH III-41
B.Market Analytics III-41
Table 49: German Recent Past, Current and Future Analysis
for Cardiac Markers by Segment - Clinical Laboratory testing
and Point-of-Care Testing (POCT) Markets: Independently
Analyzed with Annual Sales in US$ million for Years 2006
through 2015 (includes corresponding Graph/Chart) III-41

Table 50: German Historic Review Analysis for Cardiac
Markers by Segment - Clinical Laboratory testing and
Point-of-Care Testing (POCT) Markets: Independently Analyzed
with Annual Sales in US$ million for Years 2001 through 2005
(includes corresponding Graph/Chart) III-42

Table 51: German 10-Year Perspective for Cardiac Markers by
Segment - Clinical Laboratory testing and Point-of-Care
Testing (POCT) Markets: Independently Analyzed with Annual
Sales in US$ million for 2006, 2009 and 2015. III-42

2c. Italy III-43
Market Analysis III-43
Table 52: Italian Recent Past, Current and Future Analysis
for Cardiac Markers by Segment - Clinical Laboratory testing
and Point-of-Care Testing (POCT) Markets: Independently
Analyzed with Annual Sales in US$ million for Years 2006
through 2015 (includes corresponding Graph/Chart) III-43

Table 53: Italian Historic Review Analysis for Cardiac
Markers by Segment - Clinical Laboratory testing and
Point-of-Care Testing (POCT) Markets: Independently Analyzed
with Annual Sales in US$ million for Years 2001 through 2005
(includes corresponding Graph/Chart) III-44

Table 54: Italian 10-Year Perspective for Cardiac Markers by
Segment - Clinical Laboratory testing and Point-of- Care
Testing (POCT) Markets: Independently Analyzed with Annual
Sales in US$ million for 2006, 2009 and 2015 III-44

2d. United Kingdom III-45
A.Market Analysis III-45
UK Cardiovascular Diseases Fact Sheet III-45
Table 55: The UK’s Healthcare Costs of Cardio Vascular
Diseases (CVD), Coronary Heart Diseases (CHD) & Strokes in
2006 (includes corresponding Graph/Chart) III-46
Siemens and PETNET Pharmaceuticals Acquire PETNET’s New
England Operations III-46
Key Players III-46
Axis-Shield PoC III-46
B.Market Analytics III-47
Table 56: UK Recent Past, Current and Future Analysis for
Cardiac Markers by Segment - Clinical Laboratory testing and
Point-of-Care Testing (POCT) Markets: Independently Analyzed
with Annual Sales in US$ million for Years 2006 through 2015
(includes corresponding Graph/Chart) III-47

Table 57: UK Recent Past, Current and Future Analysis for
Cardiac Markers by Segment - Clinical Laboratory testing and
Point-of-Care Testing (POCT) Markets: Independently Analyzed
with Annual Sales in US$ million for Years 2001 through 2005
(includes corresponding Graph/Chart) III-48

Table 58: UK 10-Year Perspective for Cardiac Markers by
Segment - Clinical Laboratory testing and Point-of-Care
Testing (POCT) Markets: Independently Analyzed with Annual
Sales in US$ million for 2006, 2009 and 2015 III-48

2e. Rest of Europe III-49
A.Market Analysis III-49
Key Player III-49
Ani Biotech Oy III-49
B.Market Analytics III-50
Table 59: Rest of Europe Recent Past, Current and Future
Analysis for Cardiac Markers by Segment - Clinical
Laboratory testing and Point-of-Care Testing (POCT) Markets:
Independently Analyzed with Annual Sales in US$ million for
Years 2006 through 2015 (includes corresponding Graph/Chart) III-50

Table 60: Rest of Europe Recent Past, Current and Future
Analysis for Cardiac Markers by Segment - Clinical
Laboratory testing and Point-of-Care Testing (POCT) Markets:
Independently Analyzed with Annual Sales in US$ million for
Years 2001 through 2005 (includes corresponding
Graph/Chart) III-51

Table 61: Rest of Europe 10-Year Perspective for Cardiac
Markers by Segment - Clinical Laboratory testing and
Point-of-Care Testing (POCT) Markets: Independently Analyzed
with Annual Sales in US$ million for 2006, 2009 and 2015 III-51

3. Rest of the World III-52
A.Market Analysis III-52
Evolution of BNP Test market in Japan III-52
Product Launches/Approvals/Developments III-52
Strategic Corporate Developments III-53
Key Players III-54
Response Biomedical Corporation (Canada) III-54
Sekisui Medical Co. Ltd. (Japan) III-54
Shionogi and Co. Ltd. (Japan) III-54
B.Market Analytics III-55
Table 62: Rest of the World Recent Past, Current and Future
Analysis for Cardiac Markers by Segment - Clinical
Laboratory testing and Point-of-Care Testing (POCT) Markets:
Independently Analyzed with Annual Sales in US$ million for
Years 2006 through 2015 (includes corresponding
Graph/Chart) III-55

Table 63: Rest of the World Historic Review Analysis for
Cardiac Markers by Segment - Clinical Laboratory testing and
Point-of-Care Testing (POCT) Markets: Independently Analyzed
with Annual Sales in US$ million for Years 2001 through 2005
(includes corresponding Graph/Chart) III-56

Table 64: Rest of the World 10-Year Perspective for Cardiac
Markers by Segment - Clinical Laboratory testing and
Point-of-Care Testing (POCT) Markets: Independently Analyzed
with Annual Sales in US$ million for 2006, 2009 and 2015 III-56

Table 65: Rest of the World Recent Past, Current and Future
Analysis for Cardiac Markers by Assay Test Type - AMI
(CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT
proBNP) Markets: Independently Analyzed with Annual Sales in
US$ million for Years 2006 through 2015 (includes
corresponding Graph/Chart) III-57

Table 66: Rest of the World Historic Review Analysis for
Cardiac Markers by Assay Test Type - AMI (CK-MB, Cardiac
Troponin and Myoglobin), and CHF (BNP and NT proBNP)
Markets: Independently Analyzed with Annual Sales in US$
million for Years 2001 through 2005 (includes corresponding
Graph/Chart) III-58

Table 67: Rest of the World 10-Year Perspective for Cardiac
Markers by Test Type - AMI (CK-MB, Cardiac Troponin and
Myoglobin), and CHF (BNP and NT proBNP) Markets:
Independently Analyzed with Annual Sales in US$ million for
2006, 2009 and 2015 (includes corresponding Graph/Chart) III-59


IV. COMPETITIVE LANDSCAPE